In this study, we investigated whether the expression of cyclin E is affected by DNA-damaging anticancer drugs, CDDP or 5FU, in ESCC TE2 cells [29] (benign TP53 variation). The gene discussed is TP53; the disease is esophageal squamous cell carcinoma.